Sangamo: Eli Lilly and Sangamo Therapeutics enter CNS disease partnership worth over $1.4bn
The deal gives Lilly access to Sangamo's neurotropic adeno-associated virus capsid
Read full article »
Sangamo focuses on research, development and commercialization of deoxyribonucleic acid binding proteins for therapeutic gene regulation.
Read more